Jonathan Peskoff
Chief Executive Officer at F3 Platform Biologics, Inc.
Profile
Jonathan E.
Peskoff worked as a General Partner at NextPoint Partners.
He completed his undergraduate degree at the University of Southern California.
Jonathan Peskoff active positions
| Companies | Position | Start |
|---|---|---|
F3 Platform Biologics, Inc.
 F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | Chief Executive Officer | 01/01/2021 |
Former positions of Jonathan Peskoff
| Companies | Position | End |
|---|---|---|
NextPoint Partners
 NextPoint Partners Investment ManagersFinance NextPoint Partners (NextPoint Partners) is a venture capital firm founded in 1990. The firm is headquartered in Washington, District of Columbia. | Private Equity Investor | 31/01/2004 |
Training of Jonathan Peskoff
| University of Southern California | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
NextPoint Partners
NextPoint Partners Investment ManagersFinance NextPoint Partners (NextPoint Partners) is a venture capital firm founded in 1990. The firm is headquartered in Washington, District of Columbia. | Finance |
F3 Platform Biologics, Inc.
F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | Health Technology |
- Stock Market
- Insiders
- Jonathan Peskoff
